Quest PharmaTech Announces Sale of Bioceltran Investment and Return of Photodynamic Therapy Technology License

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Quest PharmaTech Announces Sale of Bioceltran Investment and Return of Photodynamic Therapy Technology License

Canada NewsWire

EDMONTON, AB, Sept. 28, 2022 /CNW/ - Quest PharmaTech Inc. (TSXV: QPT) ("Quest" or the "Company") today announced the sale of its share ownership interest in Bioceltran Co., Ltd. ("Bioceltran") to Dr. Sang Ho Jang, founder of Bioceltran, for sale proceeds of $300,0000 and the termination and return of the Photodynamic Therapy ("PDT") technology license. Bioceltran is a private, Korea based company developing skin penetrating active molecules for cosmetic and pharmaceutical use.

The Company will receive an upfront payment of $100,000 upon agreement execution and a second and final payment of $200,000 within 12 months. As part of the transaction, the PDT technology license agreement with Bioceltran for the SL017 and SL052 technologies will be terminated so that Quest has full control on the future development of the technology.

"We are pleased with this sale of our investment in shares of Bioceltran and the return of the PDT technology license to Quest for future development. Quest generated a profit from the sale of the Bioceltran shares and the return of the PDT technology will assist Quest to focus efforts on adding value to its product portfolio", commented Dr. Madiyalakan, Quest's CEO.

About Quest PharmaTech Inc.

Quest PharmaTech Inc is a publicly traded, Canadian based biopharmaceutical company (TSX-V: QPT) developing products to improve the quality of life. The company has a 42.5% ownership interest in OncoQuest Inc. which sold its immunotherapy technology to OncoQuest Pharmaceuticals, Inc. Quest also has an equity interest in OncoVent, a Chinese joint venture developing antibody-based immunotherapeutic products for cancer for the Greater China territory. Quest is also developing an antibody licensed from University of Nebraska, AR 9.6 mAb against truncated O-glycan on MUC16, for targeted cancer therapy applications. To learn more, visit www.questpharmatech.com

Forward Looking Statements

This press release includes forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based on management's expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. The information in this release is provided only as of the date of this release and the company undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Quest PharmaTech Inc.

Cision View original content: http://www.newswire.ca/en/releases/archive/September2022/28/c0834.html

Copyright CNW Group 2022

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).